ArticleFrontiers in pharmacology2026
PTPN12 is a novel biomarker associated with genomic instability, therapeutic potentials, and immunomodulator in colorectal cancer.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Protein tyrosine phosphatase non-receptor type 12 (PTPN12), a crucial enzymatic protein involved in cellular signaling, remains understudied in colorectal cancer (CRC). This study investigates this biological macromolecule's potential as a biomarker, examining its protein-protein interactions, therapeutic relevance, and immunomodulatory functions in CRC. Methods: We conducted a comprehensive analysis of PTPN12 using public datasets and clinical samples. Bioinformatics tools were employed to predict regulators and signaling pathways associated with PTPN12. Immune infiltration analysis and re-analysis of publicly available single-cell RNA sequencing (scRNA-seq) datasets were performed to explore the immunomodulatory role of PTPN12. The relationship between PTPN12 protein levels and drug susceptibility was evaluated. Functional assays validated PTPN12's role in CRC cells and its impact on oxaliplatin resistance. Results: PTPN12 protein is significantly upregulated in CRC tissues, with its elevated expression correlating with poor prognosis. PTPN12 correlates with increased genomic instability. PTPN12 is involved in various biological processes, including the regulation of cellular and developmental processes. Furthermore, high PTPN12 expression is positively correlated with stromal cell infiltration, suggesting a potential role in modulating the immune response. These findings collectively suggest that PTPN12 may have potential as a therapeutic candidate and immunotherapy-related biomarker. Knockdown of PTPN12 inhibited CRC cell proliferation, migration, and invasion. Notably, PTPN12 protein was overexpressed in oxaliplatin-resistant CRC cells, and its inhibition restored chemosensitivity in in vitro models.. Conclusion: PTPN12 shows promise as a potential biomarker and therapeutic target candidate in CRC. Our study provides preliminary insights into the role of PTPN12 in CRC pathogenesis, treatment response, and chemoresistance, which may lay the groundwork for future development of personalized therapeutic strategies pending further
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.